Cargando…

Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries

Schizophrenia-spectrum disorders are associated with substantial impairment and disability. Lack of treatment adherence is a major issue, especially in low- and middle-income countries (LMICs). Despite growing evidence supporting second-generation long-acting antipsychotics (LAIs) as an effective st...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostuzzi, Giovanni, Gastaldon, Chiara, Papola, Davide, Barbui, Corrado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121849/
https://www.ncbi.nlm.nih.gov/pubmed/35543395
http://dx.doi.org/10.1017/S2045796022000166
_version_ 1784711229421387776
author Ostuzzi, Giovanni
Gastaldon, Chiara
Papola, Davide
Barbui, Corrado
author_facet Ostuzzi, Giovanni
Gastaldon, Chiara
Papola, Davide
Barbui, Corrado
author_sort Ostuzzi, Giovanni
collection PubMed
description Schizophrenia-spectrum disorders are associated with substantial impairment and disability. Lack of treatment adherence is a major issue, especially in low- and middle-income countries (LMICs). Despite growing evidence supporting second-generation long-acting antipsychotics (LAIs) as an effective strategy to ensure continued maintenance treatment in schizophrenia, access to these technologies has been very limited in constrained-resource settings. Including second-generation LAIs in national and international essential medicines lists and evidence-based guidelines, promoting public health-oriented patent pooling and extending their availability to primary health care settings, are key actions that should urgently be implemented to increase access to long-acting technologies. Implementing these policy actions can pragmatically improve treatment adherence, ultimately tackling schizophrenia-related impairment and disability in LMICs, which can be regarded as a global health priority.
format Online
Article
Text
id pubmed-9121849
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-91218492022-06-01 Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries Ostuzzi, Giovanni Gastaldon, Chiara Papola, Davide Barbui, Corrado Epidemiol Psychiatr Sci Editorial Schizophrenia-spectrum disorders are associated with substantial impairment and disability. Lack of treatment adherence is a major issue, especially in low- and middle-income countries (LMICs). Despite growing evidence supporting second-generation long-acting antipsychotics (LAIs) as an effective strategy to ensure continued maintenance treatment in schizophrenia, access to these technologies has been very limited in constrained-resource settings. Including second-generation LAIs in national and international essential medicines lists and evidence-based guidelines, promoting public health-oriented patent pooling and extending their availability to primary health care settings, are key actions that should urgently be implemented to increase access to long-acting technologies. Implementing these policy actions can pragmatically improve treatment adherence, ultimately tackling schizophrenia-related impairment and disability in LMICs, which can be regarded as a global health priority. Cambridge University Press 2022-05-11 /pmc/articles/PMC9121849/ /pubmed/35543395 http://dx.doi.org/10.1017/S2045796022000166 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
spellingShingle Editorial
Ostuzzi, Giovanni
Gastaldon, Chiara
Papola, Davide
Barbui, Corrado
Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries
title Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries
title_full Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries
title_fullStr Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries
title_full_unstemmed Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries
title_short Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries
title_sort calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121849/
https://www.ncbi.nlm.nih.gov/pubmed/35543395
http://dx.doi.org/10.1017/S2045796022000166
work_keys_str_mv AT ostuzzigiovanni callingforpolicyactionstoincreaseaccesstolongactingantipsychoticsinlowincomeandmiddleincomecountries
AT gastaldonchiara callingforpolicyactionstoincreaseaccesstolongactingantipsychoticsinlowincomeandmiddleincomecountries
AT papoladavide callingforpolicyactionstoincreaseaccesstolongactingantipsychoticsinlowincomeandmiddleincomecountries
AT barbuicorrado callingforpolicyactionstoincreaseaccesstolongactingantipsychoticsinlowincomeandmiddleincomecountries